A Nomogram Model Based on the Inflammation-Immunity-Nutrition Score (IINS) and Classic Clinical Indicators for Predicting Prognosis in Extranodal Natural Killer/T-Cell Lymphoma

References

• Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85. doi:10.1186/s13045-017-0452-9
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005. doi:10.1182/blood-2013-01-453233
   PubMed Web of Science ®Google Scholar
• Bu S, Yuan F, Wei X, et al. L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma. Exp Ther Med. 2016;11(6):2437–2445. doi:10.3892/etm.2016.3249
   PubMed Web of Science ®Google Scholar
• Vittayawacharin P, Khuhapinant A. A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand. Hematology. 2021;26(1):75–82. doi:10.1080/16078454.2020.1867783
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400. doi:10.1016/s1470-2045(15)00533-1
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842. doi:10.1182/blood-2013-09-524108
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–618. doi:10.1200/JCO.2005.04.1384
   PubMed Web of Science ®Google Scholar
• Sun J, Ke X, Zhang M, et al. New prognostic models for extranodal natural killer T-cell lymphoma, nasal-type using Cox regression and machine learning. Transl Cancer Res. 2021;10(2):613–626. doi:10.21037/tcr-20-3017
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc3611
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Li YJ, Li ZM, Xia Y, et al. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One. 2013;8(5):e64158. doi:10.1371/journal.pone.0064158
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liang Y, Zhong D, et al. Prognostic value of inflammation-immunity-nutrition score in patients with hepatocellular carcinoma treated with anti-PD-1 therapy. J Clin Lab Anal. 2022;36(5). doi:10.1002/jcla.24336
   Web of Science ®Google Scholar
• Zhang S, Sun C, Chen X, et al. The prognostic value of controlling nutritional status (CONUT) score–based nomogram on extranodal natural killer/T cell lymphoma patients. Ann Hematol. 2023;102(6):1433–1442. doi:10.1007/s00277-023-05232-3
   PubMed Web of Science ®Google Scholar
• Wang L, Si H, Wang J, et al. Blood cell parameters as prognostic predictors of disease development for patients with advanced non-small cell lung cancer. Oncol Lett. 2020;20(2):1101–1110. doi:10.3892/ol.2020.11655
   PubMed Web of Science ®Google Scholar
• Murata M. Inflammation and cancer. Environ Health Preventative Med. 2018;23(1). doi:10.1186/s12199-018-0740-1.
   Web of Science ®Google Scholar
• Liao M, Chen P, Liao Y, et al. Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in the prognosis of hepatocellular carcinoma after surgical resection. Onco Targets Ther. 2018;11:5591–5600. doi:10.2147/ott.S167857
   PubMed Web of Science ®Google Scholar
• Li J, Chen S, Peng S, et al. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Bio Sci. 2018;14(5):549–556. doi:10.7150/ijbs.24374
   Google Scholar
• Zhang Y, Chen Q, Lu C, et al. Prognostic role of controlling nutritional status score in hematological malignancies. Hematology. 2022;27(1):653–658. doi:10.1080/16078454.2022.2078040
   PubMed Web of Science ®Google Scholar
• Lu J, Xu BB, Zheng ZF, et al. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized Phase III trial. Gastric Cancer. 2018;22(3):536–545. doi:10.1007/s10120-018-0892-0
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang Z, Zhong D, et al. The prognostic significance of inflammation-immunity-nutrition score on postoperative survival and recurrence in hepatocellular carcinoma patients. Front Oncol. 2022;12:913731. doi:10.3389/fonc.2022.913731
   PubMed Web of Science ®Google Scholar
• Jiang P, Wang J, Gong C, et al. A nomogram model for predicting recurrence of stage I–III endometrial cancer based on Inflammation-Immunity-Nutrition Score (IINS) and traditional classical predictors. J Inflamm Res. 2022;15:3021–3037. doi:10.2147/JIR.S362166
   PubMed Web of Science ®Google Scholar
• He X, Gao Y, Li Z, et al. Review on natural killer/T-cell lymphoma. Hematol Oncol. 2021;41(2):221–229. doi:10.1002/hon.2944
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon SE, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. J Hematol Oncol. 2018;11(1):1–8.
   PubMedGoogle Scholar
• Qi S-N, Xu LM, Yuan ZY, et al. Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leukemia Lymphoma. 2019;60(11):2669–2678. doi:10.1080/10428194.2019.1602265
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35(1):32–39. doi:10.1200/jco.2016.68.1619
   PubMed Web of Science ®Google Scholar
• Wan L, Wu C, Luo S, et al. Prognostic value of Lymphocyte-to-Monocyte Ratio (LMR) in cancer patients undergoing immune checkpoint inhibitors. Dis Markers. 2022;2022:3610038. doi:10.1155/2022/3610038
   PubMedGoogle Scholar
• Gawinski C, Holdakowska A, Wyrwicz L. Correlation between Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Extramural Vascular Invasion (EMVI) in locally advanced rectal cancer. Curr Oncol. 2022;30(1):545–558. doi:10.3390/curroncol30010043
   PubMed Web of Science ®Google Scholar
• Ding P, Guo H, Sun C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol. 2022;22(1):121. doi:10.1186/s12876-022-02199-9
   PubMed Web of Science ®Google Scholar
• Wang HK, Wei Q, Yang YL, et al. Clinical usefulness of the lymphocyte-to-monocyte ratio and aggregate index of systemic inflammation in patients with esophageal cancer: a retrospective cohort study. Cancer Cell Int. 2023;23(1):13. doi:10.1186/s12935-023-02856-3
   PubMed Web of Science ®Google Scholar
• Li Y-J, Jiang WQ, Huang JJ, et al. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88(5):394–399. doi:10.1002/ajh.23422
   PubMed Web of Science ®Google Scholar
• Tse E, Fox CP, Glover A, et al. Extranodal natural killer/T-cell lymphoma: an overview on pathology and clinical management. Semin Hematol. 2022;59(4):198–209. doi:10.1053/j.seminhematol.2022.10.002
   PubMed Web of Science ®Google Scholar
• He Y, Gao Y, Ping L, et al. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. J Cancer Res Clin Oncol. 2022. doi:10.1007/s00432-022-04147-2
   Web of Science ®Google Scholar